A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...

FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 7% at one stage on Monday, their biggest decline in nearly a ...

Brian Holmes is the first man in the UK and the fifth in the world to receive the treatment.

Retrospective study finds link between blockbuster drugs and longer survival ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

For the first time in 30 years, the Food and Drug Administration has approved a new treatment for an inoperable type of pancreatic cancer​.

It may be best not to go off-script when it comes to breast cancer. Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It’s the most common cancer in women ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant ...